We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+36.64%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.35B
AUM Growth
+$446M
Cap. Flow
+$266M
Cap. Flow %
19.74%
Top 10 Hldgs %
44.95%
Holding
104
New
31
Increased
29
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$40.1M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$34.3M
3
ONC
BeOne Medicines Ltd
ONC
+$23.8M
4
BIIB icon
Biogen
BIIB
+$17M
5
KROS icon
Keros Therapeutics
KROS
+$16.2M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$46.4M
2
GSK icon
GSK
GSK
+$39.6M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$26.2M
4
MREO
Mereo BioPharma
MREO
+$24.2M
5
VKTX icon
Viking Therapeutics
VKTX
+$16.4M

Sector Composition

Rank Sector Weight
1 Healthcare 84.45%
2 Consumer Staples 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$209M 15.49%
+2,200,000
New +$204M
UTHR icon
2
United Therapeutics
UTHR
$26.3B
$59.7M 4.43%
259,749
+10,300
+4% +$2.32M
FOCL
3
EDAP TMS S.A.
FOCL
$226M
$53.1M 3.94%
7,227,353
+1,012
+0% +$6.54K
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.23B
$51.9M 3.86%
3,505,000
+2,950,000
+532% +$34.3M
TEVA icon
5
Teva Pharmaceuticals
TEVA
$35.9B
$49.2M 3.65%
3,486,440
-2,078,000
-37% -$26.2M
TGTX icon
6
TG Therapeutics
TGTX
$8.58B
$48.2M 3.58%
3,168,456
+2,518,456
+387% +$40.1M
CELC icon
7
Celcuity
CELC
$4.03B
$37.4M 2.78%
1,731,338
-448,143
-21% -$7.16M
JSPR icon
8
Jasper Therapeutics
JSPR
$22.9M
$34.9M 2.59%
1,187,096
+199,998
+20% +$3.55M
NPCE icon
9
Neuropace
NPCE
$505M
$32.1M 2.38%
2,433,168
– –
EPIX
10
DELISTED
ESSA Pharma
EPIX
$30.5M 2.26%
3,589,558
-738,064
-17% -$6.44M
ORGO icon
11
Organogenesis Holdings
ORGO
$308M
$27.2M 2.02%
9,573,198
+610,198
+7% +$2.07M
AXGN icon
12
Axogen
AXGN
$2.1B
$25.1M 1.86%
3,105,815
+510,000
+20% +$4.57M
HUM icon
13
Humana
HUM
$46.7B
$25M 1.85%
72,006
-1,700
-2% -$644K
SRDX
14
DELISTED
Surmodics
SRDX
$23.5M 1.74%
800,820
+29,120
+4% +$929K
RVMD icon
15
Revolution Medicines
RVMD
$40.2B
$23.5M 1.74%
728,700
+476,700
+189% +$14.1M
IDYA icon
16
IDEAYA Biosciences
IDYA
$3.41B
$23.4M 1.74%
533,515
-31,185
-6% -$1.34M
ONC
17
BeOne Medicines Ltd
ONC
$33.8B
$23.2M 1.72%
+148,100
New +$23.8M
CCCC icon
18
C4 Therapeutics
CCCC
$376M
$20.1M 1.49%
2,458,996
+623,000
+34% +$4.83M
PEN icon
19
Penumbra
PEN
$12.5B
$19.1M 1.42%
85,700
+6,300
+8% +$1.56M
VSTM icon
20
Verastem
VSTM
$532M
$18.2M 1.35%
1,540,634
+115,000
+8% +$1.33M
KROS icon
21
Keros Therapeutics
KROS
$199M
$18.1M 1.34%
+273,600
New +$16.2M
TMCI icon
22
Treace Medical Concepts
TMCI
$259M
$17.6M 1.3%
1,345,648
+331,643
+33% +$4.42M
HCA icon
23
HCA Healthcare
HCA
$84.8B
$17.2M 1.27%
51,441
-50,059
-49% -$15.3M
NRIX icon
24
Nurix Therapeutics
NRIX
$2.43B
$16.4M 1.22%
1,115,000
+972,000
+680% +$10.5M
CSTL icon
25
Castle Biosciences
CSTL
$749M
$16.1M 1.19%
725,457
+699,457
+2,690% +$15.2M
1
2 3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Soleus Capital Management held 104 positions worth $1.35B, up 50% from $901M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Soleus Capital Management deployed $266M of net new capital in Q1 2024, opening 31 new positions and adding to 29 existing holdings. Its largest new stake was BeOne Medicines Ltd: 148,100 shares worth $23.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 100% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was GSK, an estimated $39.6M trimmed.

  • Soleus Capital Management's largest Q1 2024 buy was BeOne Medicines Ltd: 148,100 shares worth $23.2M.
  • Soleus Capital Management added most to TG Therapeutics in Q1 2024, an estimated $40.1M increase.
  • Soleus Capital Management's biggest Q1 2024 reduction was GSK, cutting an estimated $39.6M.
  • Soleus Capital Management fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $46.4M.
  • Soleus Capital Management's ten largest holdings make up 45% of its $1.35B portfolio in Q1 2024.
  • Soleus Capital Management opened 31 new positions and closed 13 in Q1 2024.
  • Soleus Capital Management's portfolio value rose 50% quarter-over-quarter to $1.35B.

Based on Soleus Capital Management's 13F filing for Q1 2024, filed 15 May 2024.